The primary actors involved in this response include the World Health Organization (WHO), which is coordinating the international response and vaccine trials, and the Democratic Republic of the Congo (DRC), the epicenter of the outbreak. Other key stakeholders include the Africa Centres for Disease Control and Prevention (Africa CDC), which is working alongside the WHO, and various international health experts deployed by the EU Health Task Force (EUHTF) to support preparedness in the DRC, Kenya, Uganda, and South Sudan. Pharmaceutical developers and research institutions are also critical, as they provide the candidate vaccines currently entering clinical trials.

The current development is the official approval of clinical trials for two new candidate vaccines to combat the Bundibugyo Ebola virus. This strain has caused a significant outbreak in the DRC, with over 10,600 confirmed cases and 5,198 deaths reported as of early November 2026. The outbreak has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. The new vaccine trials are intended to supplement existing response measures, which include contact tracing, isolation, and community engagement, as the virus has shown signs of spreading beyond the DRC into neighboring countries.

The outbreak is primarily concentrated in the Democratic Republic of the Congo, specifically affecting eight provinces including Ituri. The virus has also been detected in Kenya, Nigeria, and France, with France reporting a case involving a doctor who returned from a humanitarian mission. The geographic spread has necessitated a multi-country response, with international experts deployed to several African nations to bolster surveillance and containment efforts.

The outbreak has been ongoing since May 2026, when the WHO first declared it a PHEIC. As of November 4, 2026, the WHO has officially approved the new vaccine trials. The response has been continuous, with various milestones including the end of the outbreak in Uganda in August 2026 and ongoing monitoring by the ECDC and WHO. The situation remains fluid, with daily updates provided by the DRC government and international health bodies.

The primary motivation for the vaccine trials is the high mortality rate associated with the Bundibugyo strain and the failure of current containment strategies to fully halt the spread of the virus. The WHO and its partners are seeking to reduce the burden of the disease, which has overwhelmed local healthcare systems and caused significant social and economic disruption. The expansion of the outbreak to multiple countries has increased the urgency for effective medical countermeasures.

The response is managed through a combination of epidemiological surveillance, clinical research, and international coordination. The WHO utilizes the International Health Regulations (IHR) framework to monitor the outbreak and coordinate the response. Vaccine trials are conducted through established clinical research protocols, ensuring that safety and efficacy data are collected systematically. The deployment of experts by the EUHTF and other international bodies provides technical support to local health authorities, facilitating the implementation of standardized response measures across affected regions.